David Hughes Scales

Enhance Biotech, Inc. engages in the acquisition, development and commercialization of drugs for lifestyle disorders. The company was founded on June 7, 1999 and is headquartered in New York, NY.

Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom.

Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK